FUND III

Generating profitable returns for investors through medical device innovation
BioStar III
$91M

BioStar III had its final closing in June 2015 and employs the same strategy as BioStar II: investing primarily in early-stage medical device companies targeting the cardiology, vascular, and orthopaedics sectors. The physician led-management team and the practicing medical thought leaders who serve the firm as Medical Venture Partners (MVPs) are continuing to look for transformational medical device opportunities that are synergistic with the mission established for BioStar III.

 

Active

 

BioStar Capital

Encourages Entrepreneurs

to

APPLY FOR FUNDING

BioStar looks for technologies that:
 
Have clear regulatory pathways and defined reimbursement strategies
 
Are of interest to major medical device companies (strategics in the space)
 
Address unmet physician/patient clinical need and/or economic need
 
Have the potential to improve quality of life and longevity or fill human medical needs in a cost-effective manner